Semaglutide is a single GLP-1 receptor agonist, Tirzepatide is a dual GLP-1/GIP agonist, and Retatrutide is a triple GLP-1/GIP/glucagon agonist
Within-class differences further inform selection, as GLP-1RAs are more strongly associated with reductions in atherosclerotic events, while SGLT2is demonstrate greater benefit in HF and kidney outcomes, with modest blood pressure-lowering effects that may contribute to cardiovascular risk reduction [9]
The current formulary-driven switch, in contrast, represents a payer-initiated formulary shift rather than a supply-side limitation
Indicators of kidney damage include: Less frequent urination Fatigue Shortness of breath Nausea Chest Pain Kidney damage can have serious long-term effects on a person
BwanaBuzz Google Review The team is exceptional I truly appreciate an office that prioritizes patient education before making any decisions, and this total health and wellness team exceeds expectations
More common during dose escalation